Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Services » Servicestothe Health Industry
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| DGX | Quest Diagnostics, Inc. | -0.57% | 124.47 | 4.2% | $161.36m | |
| LH | Laboratory Corp. of America Holdings | 0.31% | 229.15 | 2.4% | $145.85m | |
| IQV | IQVIA Holdings, Inc. | -1.01% | 185.79 | 0.0% | $134.82m | |
| SYNH | Syneos Health, Inc. | 0.88% | 76.09 | 0.0% | $45.75m | |
| AMEH | Apollo Medical Holdings, Inc. | 0.72% | 22.36 | 0.0% | $2.49m | |
| BASI | Bioanalytical Systems, Inc. | -2.01% | 14.66 | 0.2% | $1.89m | |
| NRC | National Research Corp. | 1.71% | 48.31 | 0.0% | $1.62m | |
| PLX | Protalix Biotherapeutics, Inc. | -0.11% | 4.60 | 25.3% | $1.13m | |
| IDXG | Interpace Biosciences, Inc. | -3.82% | 4.03 | 22.7% | $0.56m | |
| PMD | Psychemedics Corp. | 2.24% | 5.48 | 0.7% | $0.40m |
Company Profile
Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.